Compare F5 Inc (FFIV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? F5 Inc trades at $460.11 (market cap $26.97B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: F5 Inc is far larger — about 5.5× Travere Therapeutics Inc. Common Stock's market cap, and F5 Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FFIV | TVTX | |
|---|---|---|
Market Cap | $26.97B | $4.88B |
Volume | 706,169 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $479.83 | $67.52 |
52-Week Low | $223.99 | $26.79 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | $25.61B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $457.26, down 3.43% on the day, amid a bullish technical trend and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.73 surpassing the $4.00 expectation. Revenue grew to $3.09 billion in 2025, and net income margin improved to 21.95%. Recent news highlights F5's leadership in WAAP platforms and AI security innovations, reinforcing its competitive edge.
The outlook remains positive given earnings momentum and strategic positioning in application security, though valuation multiples like a P/E of 37.95 suggest premium pricing. Risks include competitive pressures and market volatility. Analyst consensus is mixed with a $416.60 price target below the current price, indicating potential near-term caution despite long-term growth prospects.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
